Compounded vs non-compounded GLP-1 RA drug products are associated with an increased risk for adverse events such as nausea and diarrhea.

In a move that could reshape how doctors approach both weight and heart health, the American College of Cardiology (ACC) ...

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF), a global leader in food, beverage, and health and wellness, has released a new report highlighting how the rapidly growing GLP-1 consumer market is ...

A new study has suggested the benefits of GLP-1 agonists could extend to a reduction in the risk of a slew of cancers associated with being overweight. The observational study of more than 170,000 ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...

As earlier outlined, short-term studies in animals and humans have shown GLP-1 to have some direct vasorelaxation ... outcomes in patients receiving GLP1-RA therapy. There are no published studies ...

The once- and twice-daily GLP-1 RAs are now well established for their ... of exenatide b.i.d. While EQW is the only LA GLP1-RA approved by the FDA currently, there are several other formulations ...